Neutropenia
The Sernova trial is just as much at risk for this as well. Neutropenia is a side effect of the immunosuppressive drugs not the cells.The halt for neutropenia could have a crossover chilling effect on SVA stock price. Hopefully SVA has carefully dosed suppression and they better get their backsides in gear on the conformal coating. If they have a patient that goes neutropenic on such a small study we will be true bagholders until they get conformal coating in the clinic.